Siddhi Therapeutics

WHO WE ARE

A Pipeline to Change Conventional Anti-Cancer Therapies

At Siddhi Therapeutics, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients.

Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer therapies through simultaneous targeting of key drivers of disease in cancer cells without overlapping toxicities and thus preserving the quality of life in cancer patients.

  • Extramural Funding
  • Bacteria Markers
  • Nam nec mi euismod euismod
  • In aliquet dui nec lectus

1492

Laboratories in 100+ states

152

Laboratory specialists

1022

Material collection points

24332

Patients diagnosed in 2022

Clinical Trials

We have two clinical-stage investigational products for hematologic malignancies.

Clinical Trials for Siddhi Therapeutics

Siddhi Therapeutics has two clinical-stage investigational products for hematologic malignancies: tuspetinib, an oral, potent myeloid kinase inhibitor, and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor.

Clinical Trials :

  • Tuspetinib
  • Phase 1 a/b Study of Luxeptinib (CG-806) in CLL & NHL
  • Phase 1 a/b Study of Luxeptinib (CG-806) in AML